Cagrilintide Calculator
A vial strength and a water volume give a concentration. A concentration and a syringe give units. Worked for the vial sizes tracked across vendors — not generic examples.
Vial strength and water volume give a concentration; a dose then gives the unit mark it corresponds to.
Always verify calculations independently before use.
What reconstitution is
Cagrilintide, like other research peptides, ships from vendors as a lyophilized (freeze-dried) powder sealed in a vial. Reconstitution is the act of dissolving that powder in a liquid — typically bacteriostatic water — which turns a fixed mass of peptide (the vial’s labeled mg content) into a solution with a defined concentration, measurable in volume with a syringe. The mass doesn’t change; only how that mass is distributed through a volume of liquid changes.
Cagrilintide is not yet FDA-approved as a standalone product, so there is no manufacturer instruction for reconstituting it. The math below is generic pharmaceutical arithmetic (concentration = mass ÷ volume), the same relationship that governs any lyophilized compound dissolved in a diluent, applied to the vial sizes cagrilintide is actually sold in. For the compound’s mechanism, its role in the CagriSema combination, and trial evidence, see the cagrilintide profile.
What sizes does cagrilintide come in?
Two sizes, 5 mg and 10 mg, are each carried by three or more of the vendors tracked here — the smallest qualifying set of any of the calculators on this site so far, reported at that depth rather than padded to look deeper than it is. Both are read from live price data rather than a list kept by hand, which is why the calculator above offers exactly these as one-tap sizes.
| Vial size | Vendors tracking this size |
|---|---|
| 5 mg | 14 |
| 10 mg | 25 |
The arithmetic, worked
Concentration (mg/mL) equals the vial’s total mg divided by the water volume in mL. Micrograms per syringe unit, on a U-100 syringe (100 units = 1 mL), equals that concentration multiplied by 10. The table below reports both figures at two illustrative water volumes for each tracked size — as a statement of what each volume does to the concentration, not a recommendation of either:
| Vial size | At 1 mL water | At 2 mL water |
|---|---|---|
| 5 mg | 5 mg/mL — 50 mcg/unit | 2.5 mg/mL — 25 mcg/unit |
| 10 mg | 10 mg/mL — 100 mcg/unit | 5 mg/mL — 50 mcg/unit |
Doubling the water volume halves the concentration and halves the mcg delivered per unit drawn — the relationship is linear in both directions. The general dosage calculator runs this same arithmetic for any vial size and water volume, including ones outside the table above.
Units to draw, by vial size and dose
Every cell is the U-100 unit mark a given dose comes to, for a given vial strength, at 2 mL of bacteriostatic water. The rows are the two vial sizes three or more tracked vendors carry; the columns are round milligram values chosen to span the market range without reproducing any specific escalation sequence — they are not a schedule. See the cagrilintide profile for the trial evidence and the actual titration steps studied.
| Vial | 250 mcg | 500 mcg | 1,000 mcg(1 mg) | 1,500 mcg(1.5 mg) | 2,000 mcg(2 mg) | 2,400 mcg(2.4 mg) |
|---|---|---|---|---|---|---|
| 5 mg | 10.0 | 20.0 | 40.0 | 60.0 | 80.0 | 96.0 |
| 10 mg | 5.0 | 10.0 | 20.0 | 30.0 | 40.0 | 48.0 |
Figures over 100 are shown in amber: they exceed a 1 mL U-100 barrel at this water volume, so that combination does not fit one syringe. More water lowers the concentration and raises the unit count; less water does the reverse. The calculator above works any vial, volume and dose, in either direction.
What one vial comes to
Both tracked sizes, worked at 2 mL. “Doses per vial” is the vial’s total divided by the dose — how many times that amount is present in the vial, before any loss in handling.
10 mg vial at 2 mL — 5.00 mg/mL
| Dose | Units to draw | Draw volume | Doses per vial |
|---|---|---|---|
| 250 mcg | 5.0 | 0.05 mL | 40.0 |
| 500 mcg | 10.0 | 0.10 mL | 20.0 |
| 1,000 mcg (1 mg) | 20.0 | 0.20 mL | 10.0 |
| 1,500 mcg (1.5 mg) | 30.0 | 0.30 mL | 6.7 |
| 2,000 mcg (2 mg) | 40.0 | 0.40 mL | 5.0 |
| 2,400 mcg (2.4 mg) | 48.0 | 0.48 mL | 4.2 |
5 mg vial at 2 mL — 2.50 mg/mL
| Dose | Units to draw | Draw volume | Doses per vial |
|---|---|---|---|
| 250 mcg | 10.0 | 0.10 mL | 20.0 |
| 500 mcg | 20.0 | 0.20 mL | 10.0 |
| 1,000 mcg (1 mg) | 40.0 | 0.40 mL | 5.0 |
| 1,500 mcg (1.5 mg) | 60.0 | 0.60 mL | 3.3 |
| 2,000 mcg (2 mg) | 80.0 | 0.80 mL | 2.5 |
| 2,400 mcg (2.4 mg) | 96.0 | 0.96 mL | 2.1 |
What doses do clinics use?
No dose of cagrilintide has been set outside its trials, and clinics publish none of their own: they describe a once-weekly injection studied only in trials, with no approved dose. Its phase 2 trial gave 300 to 4,500 mcg (4.5 mg) once weekly; the CagriSema phase 3 trials gave 2,400 mcg (2.4 mg) with semaglutide.
- None of the eight largest US peptide clinics publishes a cagrilintide dose, and FDA states it cannot be used in compounding under federal law.
- The chart’s columns, 250 to 2,400 mcg (2.4 mg), sit inside the phase 2 trial’s range and reach the phase 3 dose; they are arithmetic, not a schedule.
Each source is listed under References, and the full clinic record is on the cagrilintide profile.
What changes the answer
- Water volume. Concentration is inversely proportional to water volume — the table above shows this directly. A larger water volume produces a lower concentration, meaning more units are needed to reach the same mg amount, which can exceed a syringe’s barrel capacity at low concentrations and high mg amounts.
- Vial size. For a fixed water volume, concentration is directly proportional to vial size — a 10 mg vial reconstituted with 1 mL is twice the concentration of a 5 mg vial reconstituted the same way.
- Syringe calibration. Every figure above assumes a U-100 syringe (100 units = 1 mL), the standard for peptide research (see the syringes and injection guide). A different calibration — U-40, for instance — would report a different units figure for the identical physical volume; it does not change the concentration or the mg delivered.
How long does reconstituted cagrilintide last?
Cagrilintide is not yet FDA-approved as a standalone product and has no manufacturer label of any kind — not for the lyophilized powder, and not for a reconstituted solution.
No manufacturer label, published study or lab document sets how long reconstituted research-grade cagrilintide remains stable, so this page states no duration. Refrigeration (2–8°C) once dissolved is standard practice, reported the same way across research peptides generally, not a figure specific to cagrilintide’s own stability.
FAQ
What is reconstitution?
Does the water volume change how much peptide is in the vial?
What syringe do the unit figures on this page assume?
Why doesn't this page say how much water to add or what dose to draw?
What if my vial's size isn't in the table below?
How much BAC water for a 5mg cagrilintide vial?
How much BAC water for a 10mg cagrilintide vial?
References
- See the cagrilintide profile for the compound’s evidence base, trial data, and regulatory status. This page reports arithmetic only and cites no additional source of its own beyond the generic reconstitution relationship (concentration = mass ÷ volume).
- Strong Health, South Florida, Cagrilintide: evidence, uses and risks; updated November 3, 2026. Read November 4, 2026. https://www.stronghealth.com/peptides/cagrilintide/
- Superpower, Cagrilintide guide; reviewed by William Maish, MD; updated October 5, 2026. Read November 4, 2026. https://superpower.com/guides/peptides/cagrilintide
- TelosRX clinical team, Cagrilintide vs semaglutide, September 1, 2026. Read November 4, 2026. https://telosrx.com/blogs/glp1/cagrilintide-vs-semaglutide-comparison
- MOPE Clinic, Metairie, Louisiana, The legal status, advantages, and risks of cagrilintide, September 17, 2025. Read November 4, 2026. https://mopeclinic.com/the-legal-status-advantage-and-risks-of-cagrilintide/
- Lau DCW, et al. Once-weekly cagrilintide for weight management (phase 2). Lancet. 2021;398:2160–72. PMID 34798060. https://pubmed.ncbi.nlm.nih.gov/34798060/
- U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Content current as of October 1, 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
Affiliate disclosure: Prof. Peptide earns a commission on purchases and sign-ups made through its links and codes, at no extra cost to the buyer. Commissions never decide which vendors are listed, how they are ranked or verified, or what Prof. Peptide concludes.
Related pages
- CagrilintideCagrilintide, a long-acting amylin analogue: weight change in its phase 2 trial, CagriSema with semaglutide in phase 3, side effects, half-life, legal status and prices.
- Cagrilintide Dosage: Trial Doses, Half-Life and What Clinics ReportCagrilintide dosage: the 300 to 4,500 mcg (4.5 mg) weekly doses of its phase 2 trial, 2,400 mcg (2.4 mg) in the CagriSema phase 3 trials, its 7- to 8-day half-life,…
- BPC-157 Calculator: Dosage & ReconstitutionReconstitution and dosage math for BPC-157 — vial size, BAC water and syringe units, worked for the sizes vendors actually sell.
- Cost Per Dose Calculator — What One Dose Costs at Each VendorEnter a compound and a dose to see what a single dose costs at each tracked vendor after Prof.
- Peptide, GLP-1 & TRT CalculatorsReconstitution, syringe-unit and half-life calculators for semaglutide, tirzepatide, retatrutide, testosterone and 25+ peptides.
Checked and updated
